Aldeyra Therapeutics (ALDX) Free Cash Flow (2013 - 2026)

Aldeyra Therapeutics (ALDX) has 14 years of Free Cash Flow data on file, last reported at -$5.1 million in Q1 2026.

• Quarterly Free Cash Flow rose 59.02% year-over-year to -$5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.0 million (up 43.14% YoY) and the FY2025 annual result came in at -$33.3 million, up 22.83% from the prior year.
• Free Cash Flow improved to -$5.1 million in Q1 2026, from -$5.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $500440.0 in Q4 2023 to a low of -$20.0 million in Q2 2022.
• A 5-year average of -$9.9 million and a median of -$10.0 million in 2024 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow surged 104.46% — and 2024, when it plunged 2505.25%.
• Tracing ALDX's Free Cash Flow over 5 years: stood at -$11.2 million in 2022, then surged by 104.46% to $500440.0 in 2023, then sank by 2505.25% to -$12.0 million in 2024, then surged by 55.97% to -$5.3 million in 2025, then increased by 3.57% to -$5.1 million in 2026.
• The last three Free Cash Flow figures came in at -$5.1 million (Q1 2026), -$5.3 million (Q4 2025), and -$7.0 million (Q3 2025), per Business Quant data.